Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NL-OMON47356
NL-OMON47356CompletedNot Applicable

Rabies antibody respons after booster vaccination, > 10 years after pre-exposure scheme (RAR-boost study) - RAR-boost study

Academisch Medisch Centrum0 sites29 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
29
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Trial ended prematurely

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • •- Healthy human volunteers in the AMC travel clinic with intradermal immunization or not completed scheme or divergent timetable intramuscular immunization more than 10 years ago.
  • •- Healthy military volunteers from the Marine Corps that received a completed intramuscular immunization more than 10 years ago and eligible for a booster immunization.

Exclusion Criteria

  • •- Age < 18 years;
  • •- No previous booster immunization;
  • •- No previous post-exposition treatment with HRIG;
  • •- Potential deployment to rabies endemic area within study period ;
  • •- Presence of a serious medical history with a potential effect on the immune system such
  • •as diabetes mellitus, HIV, functional or hyposplenia/asplenia;
  • •- Allergies to one of the components of the rabies vaccine such as chicken egg protein,
  • •polygeline, hypersensitivity to neomycin, chlortetracycline, amphotericin B and other
  • •antibiotics of the same class;
  • •- Use of mefloquine or chloroquine during the study period ;
  • •- Pregnancy ;
  • •- Breastfeeding;
  • •- Immunocompromised due to medication such as prednisolone, TNF-alfa inhibitors,
  • •*biologicals* or immunodeficiency due to humoral or cellular cause.

Investigators

Similar Trials

Completed
Not Applicable
*Dutch Marines study on Rabies antibody response after Boostering an intradermal pre-exposure scheme (MaRaBoo study)*Rabies10047438
NL-OMON45312Academisch Medisch Centrum24
Completed
Not Applicable
A Phase 1/1b First-in-human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR439459 Administered Intravenously as Monotherapy and in Combination with cemiplimab in Adult Patients with Advanced Solid TumorsAdvanced solid tumors10027655
NL-OMON55468Genzyme Europe BV12
Recruiting
Phase 3
Immune response to pre-exposure rabies vaccination via intradermal route compared to intramuscular in kidney transplant recipientsRabies neutralizing antibodyRabies vaccinationKidney transplant recipientImmune response
TCTR20200716006Ratchadapisek Sompoch Endowment Fund
Completed
Phase 3
Multicenter, open-label, extension study to characterize the long-term efficacy and safety of early versus delayed treatment with venglustat (GZ/SAR402671) in patients at risk of rapidly progressive autosomal dominant polycystic kidney disease (ADPKD)kidney diseaseADPKD
NL-OMON51229Genzyme Europe BV32
Completed
Not Applicable
A Phase Ib Open-Label, Dose-Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination with M9241 (NHS-IL12) in Subjects with Locally Advanced, Unresectable, or Metastatic Solid TumorsCancer
NL-OMON48631Merck KGaA7